You can get access to the Knowledge Base by requesting your personal account.
In order to try out and check the benefits of you can get a free trial account.
Students can request their account by selecting their associated college.


06-05-2009 - Essential substance list for horses to include drugs with

The revision of the EU legislation on maximum residue limits has lead the European Parliament to address the issue of the (un)availability of veterinary medicinal products. One of the amendments tabled by Avril Doyle MEP, the Parliament’s rapporteur for the residues legislation, relates to an amendment of the medicines Directive1 and is set to further enlarge the essential substance list for horses.
And that is good news: thanks to the amendment of Mrs Doyle, the scope of the list will be extended to substances,which bring ‘
added clinical benefit compared to other treatment options available for equidae’. So far, one of the criteria for inclusion in this list is that the substance had to be essential’ for the treatment of horses and other equidae.
Back in 1998, the (non)availability of medicines for horses was the main
reason for the creation of the Federation of European Veterinary Associations (FEEVA). Together with FVE, FEEVA booked its first huge success with the adoption of an ‘essential listof products’ for treatment of horses, end 20062. This has allowed veterinary practitioners to use drugs listed for the treatment of horses intended for human consumption. The administration of these products must be registered in the horse passport andthe withdrawal period for all products is 6 months. Horses not intended for human consumption could already be treated with these products following the so-called cascade for non-food producing animals –provided the national authority has implemented this possibility in the national legislation.
In 2009, this list will now be further extended, to allow the addition of substances with added clinical benefit.

FEEVA is currently consulting its member associations to decide, which of substances should now be reconsidered for inclusion on thegrounds of ‘added clinical benefit’.


< Back to news